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Abstract
Background: Experts in Traditional Chinese Medicine (TCM) have studied the TCM subject of
the pathogenesis of heart failure (HF) for several decades. As a result, the general idea is ben
deficiency and biao excess. However, the clinical evaluation system which combined the TCM and
western medicine in HF has not been developed yet. The objective is to establish the evaluation
index system for the integration of TCM and western medicine. The evaluation indexes which
include TCM items will specify the research design and methods.
Methods: Nine medical centers in different cities in China will participate in the trial. A population
of 340 patients with HF will be enrolled through a central randomized system for different test
groups. Group A will be treated with only western medicine, while group B with western and
Chinese medicine together. The study will last for 12 months from the date of enrollment. The
cardiovascular death will be the primary outcome.
Discussion: By putting the protocol into practice, the clinical effects of TCM for HF will be
identified scientifically, objectively as well as rationally. The proper index system which built in the
study will be helpful for the clinical effect expression of HF by integrated medicine in future.
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Background
Ancient TCM literatures have records of successful treat-
ment methods for heart failure. In modern times, medical
experts have recognized the general idea of heart failure in
TCM pathogenesis as ben deficiency and biao excess [1,2].
They have revealed the multi-mechanisms of its efficiency
of HF as well [3]. Nowadays, lots of intravenous and oral
preparations have been applied in treating HF, and con-
firmed that they're effective [4-7]. However, the forma-
tions of projects involving randomized clinical trials in
TCM are recent and their designs are not as rigorous as the
clinical trials in western medicine. In this way, neither the
conclusion which defined by death nor the special clinical
effects of TCM in HF was revealed properly. This restricted
the application and development of TCM in HF deadly.
Objective
In order to evaluate the clinical effects of heart failure and
establish a clinical effect expression of HF treated with
integrated medicine, the protocol of SECETCM-HF will be
implemented. It was strictly designed under the law of
randomized controlled trial (RCT).
Methods
Design
The multi-centre randomized controlled trial will be prac-
ticed in 9 hospitals in Tianjin, Beijing and Shanxi Province
of China. The trial begins on September 17th 2008.
Ethical Aspects
The trial was approved by the Ethics Committee of First
Teaching Hospital of Tianjin University of TCM on Janu-
ary the 30th, 2008 (TYLL2008004). It's registered in the
Chinese Clinical Trial Registry and the International Clin-
ical Trials Registry Platform of WHO as well. The protocol
and its informed consent form had been judged by the
Committee to be ethically and scientifically satisfactory to
the aims. Written informed consent must be obtained
from all participants or their representatives before enroll-
ing.
Patients
According to the inclusion and exclusion criteria, totally
340 cases with HF will be randomized into two groups,
that are Group A (regular medication group, as compari-
son) and Group B (regular medication + TCM syndrome
differentiation group).
Inclusion criteria are:
• Chronic heart failure patients (The medical history
of primary cardiovascular diseases; symptoms and
signs typical of heart failure; LVEF≤50%).
￿ Cardiac function classification: New York Heart
Association (NYHA) II ~IV.
￿ Aged 40-79.
￿ Completed and submitted informed consent form.
Exclusion criteria are:
￿ Those whose Brain Natriuretic Peptide (BNP) < 200
pg/mL
￿ Those who suffer from acute heart failure.
￿ Those who have one of the following disease: 1)
acute myocardial infarction(within the previous 4
weeks); 2) pulmonary heart disease; 3) severe valve
disease; 4) hypertrophic obstructive cardiomyopathy;
5) congenital heart disease; 6) pulmonary hyperten-
sion which was caused by acute or chronic pulmonary
embolism or other reasons; 7) pre-excitation syn-
drome; 8) stroke within 6 months; 9) acute myocardi-
tis.
￿ Those who suffer from sever hepatic or renal defi-
ciency.
￿ Those who have severe endocrine diseases like
hyperthyroidism.
￿ Those who suffer from severe anemia.
￿ Those who have mental disease.
￿ Those women who are pregnant or during the lacta-
tion period.
￿ Those who participated in other studies within the
last two months.
Western medication
According to the guidelines for chronic heart failure [8,9],
the diuretics, angiotensin converting enzyme inhibitor
(ACEI) or angiotensin receptor blocker (ARB), β-blockers,
aldosterone receptor antagonist, digitalis and vasodilating
agents could be used as the regular medication in partici-
pants. The hospitalization period is 2 ± 1 weeks.
Trial treatment
The program for Group A is as follows (Fig. 1):
Based on the regular medication, the medicines like polar-
ized solution (500 ml, Qd), which are considered as neu-
tral treatment and the same fluid volume to Group B, can
be used intravenously during the hospitalization period.
After discharging, two kinds of placebo drugs, which are
visually identical to Group B, should be selected and pre-
scribed for 6 months according to the differentiation of qi-
yang or qi-yin syndrome (Table 1). For the patients whoTrials 2009, 10:122 http://www.trialsjournal.com/content/10/1/122
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suffer from qi-yang deficiency (combined with blood sta-
sis and/or phlegm retention), the placebo drug of Qili-
qiangxin  Capsule should be taken. Conversely, the
placebo drug of Buyiqiangxin  tablets can be applied in
those with qi-yin deficiency (combined with blood stasis
and/or phlegm retention). Only one kind of them will be
taken 4 pieces each time and 3 times a day.
The program for Group B is as follows (Fig. 1):
Based on the regular medication mentioned above, dur-
ing the hospitalization period, the patients who are qi-
yang  deficient can take Shenfu  Injection (60 ml) with
5%glucose (250 ml) intravenously guttae once daily. For
those who are qi-yin deficient, Shenmai Injection (60 ml)
with 5%glucose (250 ml) can be applied intravenously
guttae once daily. For both, Danhong Injection (40 ml)
will be used with 5%glucose or physiological saline (250
ml) intravenously guttae once daily. After discharging, dif-
ferent drugs should be selected for 6 months according to
the differentiation of qi-yang  or qi-yin. For the patients
who suffer from qi-yang deficiency (combined with blood
stasis and/or phlegm retention), Qiliqiangxin  Capsule
should be taken. Conversely, Buyiqiangxin tablets can be
applied in those with qi-yin deficiency (combined with
blood stasis and/or phlegm retention). Only one of them
will be taken 4 pieces each time and 3 times a day.
Shenfu injection (Batch number: 081202), Shenmai injec-
tion (Batch number: 081125) and Danhong  Injection
(Batch number: 090410) which are used in the hospital-
ized period are made in Yaan Sanjiu Medical and Pharma-
ceutical CO. LTD, Chiatai Qingchunbao Pharmaceutical
CO. LTD and Buchang Group separately. The Qiliqiangxin
Capsule (Batch number: 080601), Buyiqingxin  Tablets
(Batch number: 080701) their models (Batch number:
080701 and M090101 separately) are supported by Hebei
Yiling Pharmaceutical CO. LTD and Suzhou Zilu Pharma-
ceutical CO. LTD freely.
Follow-up
The observing period is 12 months, which includes a 6-
month experimental medication period and a 6-month
follow-up period. At admission, discharging and each fol-
low-up point (Fig. 2), each patient's general data and their
four diagnostic results in TCM should be recorded (Table
2). During the observing period, other herbs with noted
cardiac effects are forbidden for prescription or personal
The General Process of SECE-TCM Figure 1
The General Process of SECE-TCM.Trials 2009, 10:122 http://www.trialsjournal.com/content/10/1/122
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use. The patients should be followed-up for 12 months,
except the dead ones.
Primary outcome measurement
The primary outcome measure is "cardiovascular death
incidence".
Secondary outcome measurement
The following secondary outcome measures will be
assessed:
￿ HF re-admission.
￿ Other cardiovascular events: including acute coro-
nary syndrome, serious cardiac arrhythmias, cardiac
shock, stroke, pulmonary embolism and peripheral
vascular incidences.
￿ Non-cardiovascular events: including upper gas-
trointestinal hemorrhage, kidney failure and tumor.
Measures of health-related quality of life
The Modified Minnesota Quality of Life Scale consists of
the items of its own and the additional items with TCM
characteristics. It's one of the special features in the study,
and used as an evaluation principle for HF fulfilled with
Chinese culture elements.
Measures of safety
From admission to the 3rd and 6th month interval during
the follow-up period, regular examinations should be
provided. The vital signs of the patients, such as the heart
rate and blood pressure, should be recorded before and
after treatment. Blood and urine routine examination,
hepatic and renal function, as well as electrolytes in blood
should also be tested. Moreover, ECG should be recorded
at each follow-up period. The adverse events, especially
the severe ones, should be reported to the leader of the
hospital and drug administration.
Data collection
Clinical research format should be completed at each fol-
low-up point by the investigators. All patients enrolled
will be recorded.
The statisticians from the statistics center in Tianjin Uni-
versity of Traditional Chinese Medicine and the mathe-
matics experts from Nankai University are responsible for
the statistic process and data mining.
Data collection instruments
The patients should be evaluated at the points of admis-
sion, discharging, and the 1st, 3rd, 6th, 9th, 12th month after
leaving hospital (Fig. 2). The items below should be meas-
ured:
￿ NYHA classification.
￿ Lee's heart failure score
￿ Six-minute walking test (6MWT)
￿ The scoring of the four diagnosis of TCM
￿ Quality of life scale
￿ The withdrawal and decreasing of HF drugs.
￿ General examination in clinic, including cardiac
ultrasound, chest radiography, ECG, the plasma level
of angiotensin and aldosterone, blood and urine rou-
tine examination, hepatic and renal function, as well
as electrolytes in blood.
￿ Inflammatory cytokines (TNF-α, IL-1, IL-6) and BNP
Sample size
The fatality rate of patients with HF in China is about
24.24% [10] when they are prescribed medication includ-
Table 1: The Standardization of TCM Differentiation.
Qi yang deficiency Qi yin deficiency
Main symptoms Palpitation, shortness of breath, tired and fatigue
Secondary symptoms Spontaneous perspiration, aversion to cold and cold limbs, anorexia and 
abdominal distension, loose stool, soreness and lumbago, dizziness and amnesia, 
pale complexion, dark pale tongue or pale and corpulent tongue with teeth prints, 
deep slow or irregularly intermittent pulse.
Spontaneous/night perspiration, 
dizziness and restlessness, dry mouth, 
dark red zygoma, red tongue with 
little coating, thready and rapid pulse 
or irregularly intermittent pulse.
Combined syndromes 1. Blood stasis: Dull pain on the chest, cyanotic lips, raised jugular venous pressure, dark or purple tongue with petechia, 
and hesitant pulse.
2. Phlegm retention: Swelling face and limbs or other parts of body, oliguria, chest fullness, cough with sputum, white and 
slippery tongue coating
P.S. If the patient has the main symptom, two or more secondary symptoms with the proper tongue and pulse characters, and either one or two 
item of the combined symptoms, he/she can be diagnosed as heart failure disease with certain TCM syndrome.Trials 2009, 10:122 http://www.trialsjournal.com/content/10/1/122
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ing diuretics, ACEI or ARB, β-blockers and vasodilating
agent. In a retrospective study of the First Teaching Hospi-
tal of Tianjin University of TCM, the rate was below 10%.
The power calculation is based on the fatality rates at the
5% significance level. There should be 140 patients in
each group. Concerning the loss to follow-up rate, the
study needs 340 patients in all.
Method of randomization
The central randomization system makes the study possi-
ble. The trial center gives the unique enrollment number
of each participant, then records and preserves the infor-
mation after randomization. Each hospital could assign
only 1 to 2 investigators as contact person to send the
patients' information to the central randomization sys-
tem, and get feedback on the patient's random group.
Statistical analyses
For the statistical analysis, both medical statistic method
and complex mathematical methods will be used. The
case-distribution, commeasurable analysis, patients' com-
pliance, therapeutic effect analysis, security analysis and
correlation analysis are determined by the statistical
method. Focusing on the occurrence and corresponding
time of the cardiovascular events, product-limit method,
Log-Rank test and Kaplan-Meier curve will be applied.
Meanwhile, the total risk rate will be analyzed by the Cox
proportional hazard regression. The complex mathemati-
cal methods include the rough set, random graph and
support vector machine.
Discussion
On the increasing demand of traditional medicines
(including TCM), the investigators should find a way to
Table 2: Definitions used in SECETCM-HF.
Term Definition
Differentiation By TCM diagnostic method, to differentiate patients' TCM syndrome 
comprehensively, and then determine the treating principles based on it.
Qi Deficiency Insufficiency of vital Qi or dysfunction of Qi
Yin Deficiency Insufficiency of essence, blood or body fluid
Yang Deficiency Insufficiency or dysfunction of yang Qi
Blood Stasis Unsmooth blood circulation
Phlegm Retention Concrete or invisible pathological products caused by dysfunction of body fluid 
metabolism
Cardiac Ultrasound Indexes Using improved-Simpson method to calculate ESV, EDV and EF, et al.
The information obtained by TCM four diagnostic methods The items of TCM syndromes, tongue and pulse characters by inspecting, listening to 
the sound and smelling the odors, inquiring and pulse-taking.
Quality of Life Evaluating the quality of life by Minnesota Quality of Life scale combined with TCM 
characteristic items
The Implementation of SECE-TCM Figure 2
The Implementation of SECE-TCM.Trials 2009, 10:122 http://www.trialsjournal.com/content/10/1/122
Page 6 of 6
(page number not for citation purposes)
express the characteristic clinical effects, and make it over-
spread worldwide in a sustainable way. In 1995, the
report of Office of Alternative Medicine (OAM) of Ameri-
can mentioned that "the efficiency evaluation is the core
problem" in traditional medicine [11].
Through literature review, experts consultation and epide-
miological survey, the investigators have made some
essential conclusions which involved information
obtained by TCM diagnostic method, syndrome types of
HF and the optimized TCM medication program (TCM
staging differentiation treatment) [12,13]. The informa-
tion gives supports for the protocol making and evalua-
tion index system building.
In the implementation process of the Study on the Evalu-
ation for the Clinical Effects of Traditional Chinese Medi-
cine in Heart Failure (SECETCM-HF), the regular
medication program follows the modern guideline of HF.
The systematic and comprehensive evaluation informa-
tion from clinical observing and follow-up are collected to
abstract the clinical evaluation indexes. Not only death
event, re-hospitalization and the general modern lab
indexes, but also the TCM information will be included in
the evaluation indexes system. In order to make the clini-
cal effect predominance of TCM expressed properly, all
information will be analyzed by both medical statistical
and complex mathematical methods which make the
establishment of integrated TCM and western medicine
evaluation index system possible.
Abbreviations
SECETCM-HF: Study on the Evaluation of the Clinical
Effects of Traditional Chinese Medicine in Heart Failure;
TCM: Traditional Chinese Medicine; HF: Heart failure;
RCT: Randomized controlled trial; NYHA: New York
Heart Association; BNP: Brain Natriuretic Peptide; ACEI:
Angiotensin converting enzyme inhibitor; ARB: Angi-
otensin receptor blocker; ECG: Electrocardiogram; 6MWT:
Six-minute walking test; OAM: Office of Alternative Med-
icine
Competing interests
Each author has participated sufficiently in the work to
take public responsibility for appropriate portions of the
content. All authors read and approved the final manu-
script and declare no competing interests.
Authors' contributions
JYM made substantial contributions to the conception
and design of the study and took charge of drafting the
study protocol essentially. HCS was responsible for the
evaluation on the endpoints as well as adverse events of
the study and participated in the methodological design.
YQZ, YZH, XLW, HHW, TFN, JRC, GPL, QL, LS, XLJ and
RHF took part in the coordination of the trial. BHW was
in charge of the supervising of the trail. HWW took charge
of the statistics design and the statistical analyses. JSR
dealt with the mathematic management. All authors read
and approved the final manuscript.
Acknowledgements
Study on Evaluation for the Clinical Effects of Traditional Chinese Medicine 
to Heart Failure (SECETCM-HF) is one of the National Key Technology 
R&D Programs in the 11th Five-Year Plan of China (NO. 2006BAI08B02-
01). Thanks for the following coordination hospitals: The First Teaching 
Hospital of Tianjin University of Traditional Chinese Medicine, The Second 
Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
Shanxi Traditional Chinese Medicine Institute, The Integrated Hospitals of 
TCM and Western Medicine of Shanxi University of Traditional Chinese 
Medicine, The Second Teaching Hospital of Tianjin Medical University, The 
Eastern Hospital of Beijing University of Traditional Chinese Medicine, 
Tianjin Beichen TCM Hospital, Tianjin Nankai TCM Hospital and Tianjin 
TCM Hospital.
References
1. Rui Li: The Discussion on TCM Pathogenesis of Congestive
Heart Failure.  Modern Journal of Traditional Chinese Medicine and
Pharmacy 2003, 1:13-14.
2. Mianhua Wu: Pathogenesis of Congestive Heart Failure.  Jour-
nal of Nanjing University of Traditional Chinese Medicine 2001,
17:206-209.
3. Xiaojie Lu, Fayuan Lu, et al.: The Research Progress of Mecha-
nism on Heart Failure by Herbs.  Information on Traditional Chi-
nese Medicine 2007, 24:13-15.
4. Huimin Gu: The Clinical Effects of 30 Ptients by Shenmai
Injection on Heart Failure.  Forum on traditional Chinese Medicine
2006, 7:40-41.
5. Hui Li, Xiang Liu, et al.: The clinical effects of Shenfu Injection
on Heart Failure.  Journal of Emergency in Traditional Chinese Medi-
cine 2002, 8:271-272.
6. Bo Chen, Hong Lin, et al.: The clinical research of Buyiqingxin
Pill on Chronic Heart Failure.  Chinese Journal of Geriatric Care
2005, 3:43-45.
7. Huimin Su: The influence on Qulity of Life of Heart Failure
Patients by Qiliqingxin Capsule.  Chinese Journal of Integrative
Medicine on Cardio-Cerebrovascular Disease 2007, 20:917-918.
8. Chinese Medical Association for Heart Disease, The Editorial Com-
mittee of Chinese Journal of Cardiology: Guideline for Diagnosis
and Treatment on Heart Failure.  Chinese Journal of Cardiology
2007, 12:1076-1095.
9. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA,
Rademakers FE, Marino P, Smiseth OA, De Keulenaer D, Leite-
Moreira AF, Borbély A, Édes I, Handoko ML, Heymans S, Pezzali N,
Pieske1 B, Dickstein K, Fraser AG, Brutsaert DL: How to diagnose
diastolic heart failure:a consensus statement on the diagno-
sis of heart failure with normal left ventricular ejection frac-
tion.  European Heart Journal Advance Access 2007:4.
10. Ruiqin Xie, Jun Du, Yuming Hao: The Obseraion on Coronary
Artery Disease Heart Failure by Trimetazidine.  Chinese Jour-
nal of Cardiology 2004, 32:77.
11. Levin JS, Glass TA, Kushi LH, Schuck JR, Steele L, Jonas WB: Quan-
titative methods in research on complementary and alterna-
tive medicine. A methodological manifesto. NIH Office of
Alternative Medicine.  Med Care 1997, 35:1079-1094.
12. Xiaolei Cui, Jingyuan Mao, Xianliang Wang, et al.:  Analysis of
Experts Questionnaire for TCM Pattern of Heart Failure.
Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shang-
hai 2009, 23:31-33.
13. Xiaolei Cui, Jingyuan Mao, Xianliang Wang, et al.: The application of
Delphi Method on Selecting TCM Diagnostic Items in Heart
Failure.  Liaoning Journal of Traditional Chinese Medicine 2009,
36:508-509.